Ladan Goshayeshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ladan Goshayeshi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Abbas Esmaieilzadeh
2 shared publicationsBenyamin Hoseini
2 shared publicationsFarnood Rajabzadeh
Department of Radiology School of Medicine Mashhad Branch Islamic Azad University Mashhad IR Iran
2 shared publicationsHooman Moosanen Mozaffari
2 shared publicationsKambiz Akhavan Rezayat
2 shared publicationsKamran Ghaffarzadegan
Department of Pathology, Research and Education Department, Razavi Hospital, Mashhad, Iran
2 shared publications
Latest Publications
- 25 February 2017
- Published by Mehr Publishing Group in Acta healthmedica
- Vol. 2 (2) , 194
GASTRIC, ESOPHAGEAL, AND COLON CANCERS BIOBANK IN NORTHEAST IRAN
GASTRIC, ESOPHAGEAL, AND COLON CANCERS BIOBANK IN NORTHEAST IRAN
- 25 February 2017
- Published by Mehr Publishing Group in Acta healthmedica
- Vol. 2 (2) , 194
GASTRIC, ESOPHAGEAL, AND COLON CANCERS BIOBANK IN NORTHEAST IRAN
GASTRIC, ESOPHAGEAL, AND COLON CANCERS BIOBANK IN NORTHEAST IRAN
- 25 February 2017
- Published by Mehr Publishing Group in Acta healthmedica
- Vol. 2 (2) , 172
FAMILIAL COLORECTAL REGISTRY IN NORTHEAST OF IRAN
FAMILIAL COLORECTAL REGISTRY IN NORTHEAST OF IRAN
- 25 February 2017
- Published by Mehr Publishing Group in Acta healthmedica
- Vol. 2 (2) , 172
FAMILIAL COLORECTAL REGISTRY IN NORTHEAST OF IRAN
FAMILIAL COLORECTAL REGISTRY IN NORTHEAST OF IRAN
- Open Access
- 21 May 2016
- Published by Brieflands in Razavi International Journal of Medicine
- Vol. 4 (2)
Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial
Background: Patients chronically infected with the hepatitis C virus (HCV) are more likely to have vitamin D deficiency Recent studies revealed that vitamin D has immunomodulator and antiviral properties and can enhance the effect of interferon on the HCV virus. Objectives: We aimed to assess the influence of vitamin D supplementation on viral response to PegINF/RBV therapy. Patients and Methods: In a randomized-controlled trial 66 patients with HCV (30 with genotype 1or 4 and 36 with genotype 2 or 3) were randomly divided into two groups in gastroenterology clinic: the study group (n = 34) received oral vitamin D supplementation (1600 IU/day) to maintain serum levels > 30 ng/mL besides the routine treatment of 180 μg PegINF-α2a plus oral ribavirin. The control group (n = 32) received the same treatment without vitamin D supplementation. The primary outcome was undetectable HCV-RNA at week 12 of treatment, referred to as complete early viral response (cEVR). Real-time polymerase chain reaction (sensitivity: 10 IU/mL) was used to assess HCV RNA. Serum Vitamin D levels were measured at baseline and weeks 4, 8, 12 and 24 of treatment. Spearman’s correlation showed that baseline vitamin D correlated with the stage of liver fibrosis in both study and control group (P = 0.04, r = 0.57). Results: There were no significant differences in baseline characteristics between two groups except serum AST level. Complete EVR rate at week 12 in the vitamin D group was significantly higher than the controls (100% vs 84.4%; P = 0.023) whereas this figure was not significant when genotypes 1 and 4 or 2 and 3 in the test group were compared to those of the control (100% vs 86.7%; P = 0.19 and 100% vs 82.4%; P = 0.22). Serum vitamin D levels were lowest at baseline (22 ± 15 ng/mL), but increased after 12 weeks of vitamin D therapy to a mean level of 52 ± 38 ng/mL (P = 0.02) in study group. Conclusions: The addition of vitamin D to conventional PegIFN/RBV therapy in HCV patients may significantly improve the viral response. Keywords: Hepatitis C; Vitamin D; Early Virologic Response
- 21 May 2016
- Published by Brieflands in Razavi International Journal of Medicine
- Vol. 4 (2)
Open AccessVitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial
Background: Patients chronically infected with the hepatitis C virus (HCV) are more likely to have vitamin D deficiency Recent studies revealed that vitamin D has immunomodulator and antiviral properties and can enhance the effect of interferon on the HCV virus. Objectives: We aimed to assess the influence of vitamin D supplementation on viral response to PegINF/RBV therapy. Patients and Methods: In a randomized-controlled trial 66 patients with HCV (30 with genotype 1or 4 and 36 with genotype 2 or 3) were randomly divided into two groups in gastroenterology clinic: the study group (n = 34) received oral vitamin D supplementation (1600 IU/day) to maintain serum levels > 30 ng/mL besides the routine treatment of 180 μg PegINF-α2a plus oral ribavirin. The control group (n = 32) received the same treatment without vitamin D supplementation. The primary outcome was undetectable HCV-RNA at week 12 of treatment, referred to as complete early viral response (cEVR). Real-time polymerase chain reaction (sensitivity: 10 IU/mL) was used to assess HCV RNA. Serum Vitamin D levels were measured at baseline and weeks 4, 8, 12 and 24 of treatment. Spearman’s correlation showed that baseline vitamin D correlated with the stage of liver fibrosis in both study and control group (P = 0.04, r = 0.57). Results: There were no significant differences in baseline characteristics between two groups except serum AST level. Complete EVR rate at week 12 in the vitamin D group was significantly higher than the controls (100% vs 84.4%; P = 0.023) whereas this figure was not significant when genotypes 1 and 4 or 2 and 3 in the test group were compared to those of the control (100% vs 86.7%; P = 0.19 and 100% vs 82.4%; P = 0.22). Serum vitamin D levels were lowest at baseline (22 ± 15 ng/mL), but increased after 12 weeks of vitamin D therapy to a mean level of 52 ± 38 ng/mL (P = 0.02) in study group. Conclusions: The addition of vitamin D to conventional PegIFN/RBV therapy in HCV patients may significantly improve the viral response. Keywords: Hepatitis C; Vitamin D; Early Virologic Response
- Open Access
- 1 April 2014
- Vol. 6 (2) , 93-97
The Clinical Presentation of Celiac Disease: Experiences from Northeastern Iran
BACKGROUND This study aimed to explore demographic characteristics and clinical presentations of celiac disease (CD) in Northeastern Iran. METHODS This was a cross-sectional retrospective study of 193 adults with CD who presented to Mashhad University Gastroenterology Clinic between 2008 and 2013. Patient data that included mode of presentation and the presence of any concomitant illnesses were collected. Intestinal biopsy and serum anti-tissue transglutaminase (anti-tTG) were used for diagnosis. Mucosal lesions were classified according to modified Marsh classification. RESULTS Overall, 132 females and 61 males, with a mean age at diagnosis of 32.6 ± 13.2 years were included. The patient's chief complaints in order of decreasing frequency were dyspepsia (24.6%), diarrhea (20%), anemia (12.8%), and flatulence (7.2%). Bone disease was seen (osteopenia, osteoporosis) in 30% of patients. A positive family history of CD was found in 17.9% of cases. There were 64% who had serum anti-tTG >200 units/ml and 78% had a Marsh classification grade 3 on duodenal biopsy. The histology grade (Marsh) did not show any correlation with anti-tTG serum levels, age, body mass index (BMI) or hemoglobin levels. CONCLUSION In Northeastern Iran, CD was seen more commonly in females and with non-diarrheal presentations. Abdominal discomfort, anemia and bone disease were most common primary presentations in this area. Histology grade showed no significant correlation with level of anti-tTG, BMI or hemoglobin levels. We suggest screening for CD in unexplained abdominal discomfort, bone disease and anemia.
- 1 April 2014
- Vol. 6 (2) , 93-97
Open AccessThe Clinical Presentation of Celiac Disease: Experiences from Northeastern Iran
BACKGROUND This study aimed to explore demographic characteristics and clinical presentations of celiac disease (CD) in Northeastern Iran. METHODS This was a cross-sectional retrospective study of 193 adults with CD who presented to Mashhad University Gastroenterology Clinic between 2008 and 2013. Patient data that included mode of presentation and the presence of any concomitant illnesses were collected. Intestinal biopsy and serum anti-tissue transglutaminase (anti-tTG) were used for diagnosis. Mucosal lesions were classified according to modified Marsh classification. RESULTS Overall, 132 females and 61 males, with a mean age at diagnosis of 32.6 ± 13.2 years were included. The patient's chief complaints in order of decreasing frequency were dyspepsia (24.6%), diarrhea (20%), anemia (12.8%), and flatulence (7.2%). Bone disease was seen (osteopenia, osteoporosis) in 30% of patients. A positive family history of CD was found in 17.9% of cases. There were 64% who had serum anti-tTG >200 units/ml and 78% had a Marsh classification grade 3 on duodenal biopsy. The histology grade (Marsh) did not show any correlation with anti-tTG serum levels, age, body mass index (BMI) or hemoglobin levels. CONCLUSION In Northeastern Iran, CD was seen more commonly in females and with non-diarrheal presentations. Abdominal discomfort, anemia and bone disease were most common primary presentations in this area. Histology grade showed no significant correlation with level of anti-tTG, BMI or hemoglobin levels. We suggest screening for CD in unexplained abdominal discomfort, bone disease and anemia.
- Open Access
- 19 November 2013
- Published by Brieflands in Hepatitis Monthly
- Vol. 13 (11) , e12427
Cholestasis and Seizure Due to Lead Toxicity: A Case Report
Introduction: A 65-year-old man presented to the emergency department with abdominal pain, abnormal liver function tests (cholestatic pattern), and normocytic anemia. He had been an opium user for 20 years. Clinical and preclinical findings including the bluish discoloration of periodontal tissues, or Burton’s sign, and generalized ileus on abdominal x-ray led us to the possibility of lead poisoning. Lead levels were higher than normal (150 µg/dL). Magnetic resonance cholangiopancreatography (MRCP) and abdominal ultrasound were performed to rule out extra hepatic causes of cholestasis. Case Presentation: To evaluate the possibility of lead-induced hepatotoxicity, a liver biopsy was performed. Histological features of lead-induced hepatotoxity have rarely been described in humans. In this patient, focal canalicular cholestasis and mild portal inflammation were confirmed. Conclusions: Thus, treatment with ethylenediaminetetraacetic acid (EDTA) and British anti-lewisite (BAL) were initiated and continued for five days. The patient's liver function tests returned to their normal values, clinical findings including nausea, vomiting, and abdominal pain subsided, and the patient was discharged from the hospital in good condition. Keywords: Lead; Cholestasis; Opium
- 19 November 2013
- Published by Brieflands in Hepatitis Monthly
- Vol. 13 (11) , e12427
Open AccessCholestasis and Seizure Due to Lead Toxicity: A Case Report
Introduction: A 65-year-old man presented to the emergency department with abdominal pain, abnormal liver function tests (cholestatic pattern), and normocytic anemia. He had been an opium user for 20 years. Clinical and preclinical findings including the bluish discoloration of periodontal tissues, or Burton’s sign, and generalized ileus on abdominal x-ray led us to the possibility of lead poisoning. Lead levels were higher than normal (150 µg/dL). Magnetic resonance cholangiopancreatography (MRCP) and abdominal ultrasound were performed to rule out extra hepatic causes of cholestasis. Case Presentation: To evaluate the possibility of lead-induced hepatotoxicity, a liver biopsy was performed. Histological features of lead-induced hepatotoxity have rarely been described in humans. In this patient, focal canalicular cholestasis and mild portal inflammation were confirmed. Conclusions: Thus, treatment with ethylenediaminetetraacetic acid (EDTA) and British anti-lewisite (BAL) were initiated and continued for five days. The patient's liver function tests returned to their normal values, clinical findings including nausea, vomiting, and abdominal pain subsided, and the patient was discharged from the hospital in good condition. Keywords: Lead; Cholestasis; Opium